The world’s largest medtech company acquired the technology by purchasing MC3 Cardiopulmonary in March. Medtronic described the deal as the culmination of MC3’s eight-year partnership and distribution agreement with the Medtronic Cardiac Surgery business. The partnership resulted in the introduction of seven new ECMO products in seven years.
VitalFlow is a configurable one-system ECMO system, designed to provide simplicity and performance. Company officials described it as bridging the gap between bedside care and intra-hospital transport. The goal is provide physicians and clinicians an easier, smarter ECMO experience.
“The launch of this technology further underscores Medtronic’s unwavering dedication to developing life-restoring medical devices that address both acute and chronic cardiopulmonary clinical needs, and demonstrates our sustained commitment to this vital field,” said Karim Bandali, president of the Cardiac Surgery business within the Cardiovascular portfolio at Medtronic.
“This announcement builds on our recent acquisitions, including a Viant Medical contract manufacturing site and the Penditure left atrial appendage exclusion system. Clinicians can continue to expect a global cadence of bold and unique innovations, focused on addressing diverse clinician needs while enhancing our ability to meet the needs of all cardiac surgery patients.”
Medtronic says it is seeking to build the most robust cardiac surgery portfolio, serving the whole heart care team of cardiac surgeons and perfusionists,
